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3“Kroppen behöver hjärtat för att pumpa blod, men man    
behöver också kärlek. Då pumpar hjärtat bättre.”     
                                                                               Matilda, 7 år        
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5ABSTRACT
Background: The use of a conduit is an established surgical method for reconstruction of the right 
ventricular outfl ow tract in congenital heart disease. The most commonly used conduit is a homo-
graft.  Its limited durability makes reinterventions almost inevitable but the actual durability of a 
conduit in the adult population is poorly described. The introduction of transcatheter pulmonary 
valve replacement (TPVR) has expanded the possibilities for conduit reintervention but the impact 
of this new technique on clinical practice is unknown. Furthermore, little is known on the infl uence 
of reinterventions on quality of life. Conduit surgery and reintervention is among the most common 
surgical procedures in adult congenital heart disease but relative lack of knowledge complicates 
decision making.
Method: Paper 1: The PubMed database was searched in May 2015 with the terms “homograft 
AND pulmonary valve,” generating 665 hits. Studies involving more than 50 patients with a mean 
or median age >18 years were included. Papers 2–4: The Swedish registry of congenital heart dis-
ease (SWEDCON) was used to collect data. Patients were identifi ed by codes for classifi cation of 
surgical procedures and a group variable specifi c for patients with a conduit. 
Results: Paper 1: Six studies with a cumulative total of 560 patients were found and included. 
Perioperative mortality was 0%–2.9%, and long-term mortality was 2%–8.8% at 8.1–10 years. Re-
interventions of homografts were common during patients’ lifespans, with a 10-year event-free sur-
vival of 78%–80%. Early postoperative echocardiographic or magnetic resonance imaging defects 
appear to predict rapid homograft degeneration. Paper 2: Data on quality of life (EQ-5D) from the 
fi rst and latest visit were collected from 103 patients with a mean age of 31 years. Mean time from 
fi rst to latest visit was 3 years. Health perception (mean EQ-VAS) declined from 84.4 (SD=14.6) 
at the fi rst visit to 78.6 (SD=18.3) at the latest visit (P=0.001). This decline was not observed in 
patients with reinterventions between visits (n=18). Low EQ-VAS was associated with symptoms 
and NYHA class II–IV. Problems in the EQ-5D dimension “usual activities” were more common in 
patients with reinterventions (25%) than in those without reinterventions (7%) (P=0.04). Paper 3: 
From 2000 to 2014, there was an increase in the number of adult patients with conduits from 122 
to 536, including 60 surgical conduit replacements, 40 TPVRs, and 176 new conduit implantations. 
There was a signifi cant increase in new implantations (P=0.007) and surgical conduit replacements 
(P=0.024) across all three time periods. Patients with new implantations were older (median age, 
32 years) compared with those in the reoperation and TPVR groups (median age, 26 years), with 
the majority of patients having tetralogy of Fallot (57%). The majority of conduit reinterventions 
were surgical also after the introduction of TPVR in 2007, with no signifi cant difference regarding 
diagnosis, gender, age, or previous number or longevity of conduits between surgical replacement 
and TPVR. Paper 4: A total of 574 patients with a conduit (mean age 36.1 years) were identifi ed. 
Tetralogy of Fallot represented the largest group (45%). There were 769 operations and 50 TPVRs. 
Long-term survival after the fi rst conduit operation (mean age 20.2 years) including periopera-
tive mortality (<1%) was 93% at 20 years. The most common cause of death was cardiac-related. 
Higher age at fi rst conduit operation was associated with an increased mortality risk. Event-free 
survival was 77% and 54% at 10 and 20 years, respectively. Ten-year event-free survival after the 
fi rst conduit reintervention (n=176) was 70%, signifi cantly lower than after the fi rst conduit opera-
tion (P=0.04). Higher age at the fi rst conduit operation had a protective association, whereas male 
gender and complex malformations were associated with an increased risk of further reintervention.
Conclusion: Patients perceive a decline in their health over time after right ventricular outfl ow 
tract surgery. This decline was not observed in patients with further reinterventions. The number 
of patients with a conduit is increasing, and reinterventions for conduits are common. Since the in-
troduction of TPVR, less than half of all patients with conduit failure are treated by this technique.
Long-term mortality after conduit surgery and reinterventions is low, but the need for conduit rein-
terventions is substantial. Perioperative mortality is low in relation to cardiac-related death.
Keywords: congenital heart disease • RVOT surgery • conduit • quality of life • outcome • TPVR.
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7 SAMMANFATTNING PÅ SVENSKA
En grupp patienter med medfött hjärtfel saknar eller har en underutvecklad lungartär, 
dvs koppling mellan höger kammare och lungcirkulationen. Den största gruppen om-
nämns ibland som ”blue babies” och innefattar patienter med Fallots tetrad som utgör 
ca 10% av alla medfödda hjärtfel. Många av dessa patienter har opererats som barn 
med palliativ kirurgi i form av en shunt som säkerställer lungblodfl ödet men även 
tidigt korrektivt syftande kirurgi utförs. Hos många patienter måste en kirurgisk kopp-
ling mellan höger kammare och lungartären skapas, en sk conduit. Denna metod har 
använts sedan 60-talet men i allt större omfattning. Utvecklingen av barnhjärtkirurgin 
har varit enastående med ökande överlevnad till följd och nu fi nns fl er vuxna än barn 
med komplexa medfödda hjärtfel. Då hållbarheten av conduiten är begränsad behövs 
nya operationer och kateteringrepp under patientens livstid för att säkerställa en god 
hjärtfunktion. Att patienten har ett livslångt behov av uppföljning och ofta genomgår 
fl era kirurgiska ingrepp gör att även att tillståndet kan tänkas påverka livskvaliteten.
Denna avhandling syftar till att studera vuxna patienter i Sverige med conduit med 
avseende på livskvalitet, trender avseende behandling samt överlevnad och behov av 
nya operationer eller kateteringrepp.
Studien har gjorts med hjälp av det svenska kvalitetsregistret för medfödda hjärtfel, 
SWEDCON. Ungefär 1000 vuxna patienter har genomgått någon form av kirurgi av 
kopplingen mellan höger kammare och lungartären. Av dessa har 574 stycken en sk 
conduit varav ca 70% är av typen homograft dvs består av vävnad från avlidna do-
natorer. Antalet vuxna patienter med conduit har fyrfaldigats under 2000-talet både 
genom överföring av patienter från barnsjukvården men även genom operation av 
vuxna patienter. Antalet conduitoperationer har också ökat kraftigt i denna tidsperiod, 
såväl nya implantationer som reoperationer. Kateterburen klaffi mplantation introdu-
cerades i Sverige 2007 och utgör sedan dess knappt hälften av reoperationerna. I valet 
mellan öppen operation eller kateterburen klaffi mplantation hade diagnos, kön, ålder 
samt antal eller hållbarhet av tidigare conduits hade ingen betydelse. Patienternas ge-
nerella hälsorelaterade livskvalitet mättes med det validerade hälsoskattningsformu-
läret EQ-5D. Vi kunde här konstatera att patienternas självskattade hälsa försämrades 
över tid. De som genomgick någon form av ingrepp mellan mätningarna försämrades 
dock inte. Det fanns också en koppling mellan sämre hälsoskattning och förekomst av 
symtom eller försämrad funktionsklass (NYHA). Långtidsöverlevnaden efter första 
conduitoperationen är tämligen god, över 90% efter 20 år. Dödligheten inom 30 dagar 
från operation är mindre än 1% även inkluderande reoperationer. De patienter som av-
lidit under studiens gång hade i majoriteten av fallen orsakats av hjärtsjukdom. Högre 
ålder vid första korrigerande operation med conduit var förenat med ökad dödlighet. 
Överlevnad utan reoperation eller kateterburen hjärtklaffi mplantation var 54% efter 
20 år vilket indikerar att det är var mycket vanligt med förnyade ingrepp. Manligt 
kön, låg ålder eller att ha mer komplex anatomi var associerat med kortare tid till nytt 
ingrepp eller död. Analys av överlevnad utan reoperation eller perkutan klaffi mplanta-
tion i befi ntlig conduit visade att denna verkar vara signifi kant sämre jämfört med den 
första operationen.
8Vi drar slutsatsen att långtidsöverlevnaden efter conduitoperation är tämligen god 
men begränsas i första hand av hjärtorsakad död. Behovet av nya ingrepp för att sä-
kerställa en god hjärtfunktion är stor. Hållbarheten vid reoperation är kortare än vid 
första operationen vilket är oroande i ljuset av att fl er och fl er patienter behöver upp-
repade ingrepp. Då patienten har ett livslångt behov av uppföljning och nya ingrepp 
är livskvalitetsaspekten viktig och bör beaktas.
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ABBREVIATIONS
GUCH   grown-up congenital heart disease
CHD   congenital heart disease
PVR   pulmonary valve replacement
TPVR   transcatheter pulmonary valve replacement
TOF   tetralogy of Fallot
RVOT   right ventricular outfl ow tract
RV   right ventricular
PA   pulmonary artery
RV-to-PA  right ventricle to pulmonary artery (conduit)
PR   pulmonary valve regurgitation
PS   pulmonary stenosis
VSD   ventricular septal defect
SWEDCON  Swedish registry of congenital heart disease
MRI   magnetic resonance imaging
VT   ventricular tachycardia
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INTRODUCTION
I had the opportunity to start a clinical fellowship at the Grown-Up Congenital Heart Disease (GUCH) Center at Sahlgrenska University hospital/Östra in 2011. 
During my fi rst months of practice, I remember meeting patients with conduits, many 
of them with conduit replacements because of conduit failures before they reached 
adulthood. Despite this, many patients seemed to live a good life. This raised several 
questions for me and, in some cases, for the patients. Today, on reading my notes 
from the course “Introduction to research” for PhD students, I found the following 
questions:
How is health-related quality of life affected in these patients, given that conduit 
reinterventions are common? Is this a growing group of patients, since more 
patients with congenital heart disease are reaching adulthood? What is the im-
pact of transcatheter pulmonary valve replacement, and is surgery needed less 
frequently now? What is the long-term survival and what is the lifetime mortal-
ity after reinterventions? What is the expected event-free survival after conduit 
surgery and after conduit reinterventions? Can we expect improved conduit lon-
gevity after conduit reinterventions, since somatic growth is no longer a factor?
The subject of this thesis was chosen following my own observations of adults with 
conduits and their almost inevitable need for repeated surgery or reinterventions dur-
ing their lifetime. This thesis highlights adult patients with a conduit as viewed from a 
congenital cardiologist’s perspective. Many cardiologists will meet such patients, all 
of whom are in need of lifetime follow up.
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BACKGROUND
Malformations of the right ventricular outfl ow tract (RVOT)
There are several cardiac malformations for which a conduit is used for reconstruction 
of the right ventricular outfl ow tract (RVOT). Such malformations can present in dif-
ferent phenotypes ranging from mild to severe. This is a brief presentation of relevant 
malformations in conduit surgery and a few relevant clinical aspects.
Tetralogy of Fallot (TOF) is named after Étienne-Louis Arthur Fallot who described 
the condition in 1888. It is the most common cyanotic congenital heart defect, consist-
ing of ventricular septal defect (VSD), overriding aorta, pulmonary stenosis, and right 
ventricular hypertrophy (1). The patients are sometimes referred to as “blue babies” 
and represent around 10% of all congenital heart malformations, with a male predom-
inance. Adults with TOF who are considered for conduit surgery mainly fall into the 
following categories: (a) patients operated on as children for TOF using a transannular 
patch, leaving the patient with severe pulmonary valve regurgitation (PR); (b) patients 
with TOF who undergo subvalvular resection and/or valvular commissurotomy while 
remaining at risk for PR and late RV failure; (c) patients who undergo conduit surgery 
in early life in cases where the RVOT is not amenable to surgical repair (Figure 1).
Figure 1. Anatomy of Tetralogy of Fallot composed of its four features: pulmonary stenosis, 
VSD, right ventricular hypertrophy and overriding aorta. (Courtesy of Boris Nilsson)
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Pulmonary valve abnormalities can present both as isolated forms and in association 
with other lesions. The most common forms are valvular and subvalvular stenosis, 
followed by supravalvular stenosis (Williams or Noonan syndrome). Subvalvular ste-
nosis can also arise from RV hypertrophy. Patients presenting at the GUCH unit as 
adults often have undergone intervention with balloon valvuloplasty or surgical com-
missurotomy as children and now present with severe PR and a large right ventricle. 
Subinfundibular stenosis and double-chambered right ventricle can also be present 
and in association with VSD.
Pulmonary atresia with VSD has similarities to TOF and is sometimes referred to as 
an “extreme Fallot.” It varies from simple to complex forms, which can have atresia 
of both the main pulmonary artery (PA) and PA branches. Major aortopulmonary col-
lateral arteries (MAPCA) from the aorta to the pulmonary circulation are common. 
Surgical management has similarities to that applied to TOF. Pulmonary valve atresia 
with intact ventricular septum is a different entity to PA with VSD, and is character-
ized by a hypoplastic right ventricle and ductus or coronary fi stulas supplying blood to 
the lungs. If the RV size is adequate, biventricular repair is possible, and an RV-to-PA 
conduit can be used to establish RV-to-PA continuity.
Double-outlet right ventricle presents with great variation from Fallot-like to single-
ventricle physiology. Surgical management using an RV-to-PA conduit is often pos-
sible.
Truncus arteriosus basically consists of a single artery arising from the heart supply-
ing both systemic and pulmonary circulation. It also presents with great variation, 
with a commonly applied classifi cation. Surgical repair in early life includes estab-
lishing RV-to-PA continuity through a conduit arising from the right ventricle via a 
ventriculotomy (2).
Transposition of the great arteries is described as a malformation whereby the aorta 
arises from the right ventricle and the PA from the left ventricle. VSD and pulmonary 
outfl ow obstructions are commonly associated lesions. In the presence of a large and 
subaortic VSD a Rastelli operation can be performed, using the VSD to direct blood 
from the left ventricle to the aorta. A conduit is then used to connect the right ventricle 
to the PA via a ventriculotomy, thus surgically creating an RVOT (3) (Figure 2). 
Aortic valve stenosis in early life is often treated with commisurotomy. Further man-
agement in young patients for avoiding small sized valve prosthesis includes the Ross 
procedure where the aortic valve is reconstructed using the native PA, which is trans-
located to the aortic position (4). The PA is then reconstructed with a conduit. Thus it 
is not a malformation of the RVOT.  The method is also used in selected adult patients 
with aortic valve disease for example after endocarditis (Figure 3). 
Initial surgical repair
Surgical management of RVOT problems is sometimes staged, but initial repair is 
also possible. Management in early life often includes palliative procedures such as 
16
Figure 2. Illustration of the Rastelli operation for transposition, VSD and pulmonary steno-
sis. The VSD is closed directing the blood from the left ventricle to the aorta via a ventricu-
lotomy of the anterior wall of the right ventricle. A conduit is then used to connect the right 
ventricle to the pulmonary artery. (Courtesy of Boris Nilsson)
Figure 3. Illustration of the Ross procedure.  The aortic valve is reconstructed using the 
native pulmonary artery as an autograft with reimplantation of the coronary arteries. The 
pulmonary artery is then reconstructed with a conduit. (Courtesy of Boris Nilsson)
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a Blalock–Taussig shunt connecting the subclavian artery to the PA. Initial surgical 
repair is possible, for example, in patients with TOF, whereby the VSD is closed and 
RVOT obstruction relieved. Late management is most commonly for PR but can also 
be used for RVOT obstruction. There has been a trend over time toward avoidance of 
transannular procedures, thus attempting to preserve pulmonary valve annulus integ-
rity when possible (5). When the RVOT is not amenable to repair, a valved conduit 
can be used for reconstruction. Surgical reconstruction of the RVOT with a conduit 
(homograft) has been performed since the 1960s (6). This advance has led to excellent 
palliation for affected patients. In many countries the use of biological valves in the 
RVOT is common for TOF. However, in Sweden a conduit, preferably a homograft, is 
considered the treatment of choice. The placement of biological valves in pulmonary 
locations is rarely implemented.
Rastelli repair for transpositions with VSD and repair of the truncus arteriosus are 
somewhat different in this setting in that they lack native RVOT. This leaves the sur-
geon with the task of reconstructing not only the PA and valve but also the entire 
RVOT. These malformations, as well as double-outlet right ventricle and pulmonary 
atresia, are rarely reconstructed after childhood, although cases of late reconstructions 
in adults have been reported.
The evolution of surgery has reduced mortality in children to the extent that the num-
ber of adults with complex congenital heart disease (CHD) now outnumbers child-
hood counterparts (7-9).
Management of native or postoperative RVOT dysfunction
Despite successful initial repair, reoperation with pulmonary valve replacement (PVR) 
is common later in life. However, clinical outcome data after PVR are inadequate and 
sometimes confl icting, and robust data for the optimal timing of PVR are not avail-
able. Studies on the effects of PVR are most often conducted on surrogate variables or 
matched comparisons, primarily from patients with TOF for whom clinical practice is 
analogous to that for Fallot-like (pulmonary atresia with VSD) and other malforma-
tions (10). In asymptomatic patients there is even less evidence for the timing of PVR, 
refl ected in the wide variations in referral patterns in asymptomatic patients (11). 
There are also variations in age at PVR, indicating insuffi cient scientifi c support (12). 
Suggestions for managing these patients, taking into account several aspects besides 
symptoms such as tricuspid valve regurgitation, biventricular function and size, ex-
ercise capacity, arrhythmias, and symptom progression over time, are available (13).
One of the great challenges in patients with RVOT dysfunction is the tradeoff between 
the potential benefi ts and risks of RVOT intervention. All valves or conduits essen-
tially become dysfunctional over time. Moreover, since life expectancy of the patient 
is longer than the expected longevity of the implanted valve, this tradeoff will take 
place repeatedly throughout the patient’s life. Management is even more complex, as 
this is a heterogeneous population with various malformations and previous surgery. 
Data reporting an increasing number of adults with complex CHD indicate that this 
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clinical problem will only continue to grow in the future (7). PVR and conduit surgery 
are among the fastest growing segments of CHD and the most common surgical pro-
cedures in adults with CHD in the United Kingdom (14). Furthermore, the number of 
PVRs increased annually from 2004 to 2012 in both children and adults in a survey 
of 35 centers in the United States (12). Given the necessity for reoperations, multiple 
reoperations or reinterventions are often needed before the patients reach adulthood 
(15). In a retrospective study of repeated sternotomy for RVOT reconstruction, re-
searchers found no evidence of increased risk for repeated sternotomies in a study of 
220 patients with RVOT reconstruction (16).
Indications for pulmonary valve replacement (PVR)
At this point some brief comments on clinical aspects of native or postoperative 
RVOT obstructions are pertinent. Patients with PS often have more symptoms than 
those with PR. Doppler gradients can be misleading (overestimation) in long stenosis 
or stenosis in series, which is often the case in patients with conduits. Furthermore, le-
sions are often combined. There is consensus, refl ected in European Society of Cardi-
ology (ESC) guidelines, to relieve RVOT obstructions (in native or postsurgical TOF 
or conduit) when RV pressure is more than 60 mmHg in symptomatic patients. For 
asymptomatic patients 80 mmHg is recommended or when arrhythmias, progressive 
RV size or function impairment, or progressive tricuspid valve regurgitation occurs.
In the American College of Cardiology/American Heart Association guidelines from 
2008, the recommendation regarding RV pressure is even lower, at 50 mmHg. For 
those with severe PR there is consensus to recommend PVR in symptomatic patients. 
For asymptomatic patients PVR should be considered when arrhythmias, progressive 
RV size or function impairment, or progressive tricuspid valve regurgitation occurs 
(10, 17) (Table 1).
Reconstruction of the RVOT and reintervention
Various methods have been used for reconstruction of the pulmonary valve and 
RVOT, all of which unfortunately become dysfunctional over time and need replace-
ment or reintervention (18). Choice of valve or conduit is dependent on factors such 
as anatomy, age, and local routine. By far the most commonly used method in Sweden 
is a homograft conduit, although there are also biological and mechanical alternatives. 
Increasing recognition for transcatheter pulmonary valve replacement (TPVR) has ex-
panded the possibilities for reintervention in conduits where earlier only stenting was 
performed. TPVR has also been reported to be feasible for reintervention in native 
RVOT. Clinical practice in Sweden, however, is limited to reintervention in conduits. 
Conduits
Homograft
The fi rst experience of RVOT reconstruction with a homograft was by Ross and 
Somerville in 1966 (6). Homograft (or allograft) is tissue from human diseased do-
nors that is explanted under sterile conditions shortly after death. Both pulmonary and 
aortic origins are exploited. There are several different techniques for preservation 
such as irradiation, cryopreservation (below −150°C), and refrigeration (+4°C). Prior 
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to storage in the homograft bank, the graft is sterilized with a solution of antibiot-
ics. At implantation, homografts have technical advantages such as good hemostatic 
properties (19, 20). Homografts also have good hemodynamic characteristics and low 
rates of thromboembolism, which makes anticoagulation unnecessary. There are also 
reports on lower incidence of endocarditis with homografts in comparison with bio-
logical alternatives (21). Obvious disadvantages are the limited number of donors and 
limited access to valve banks.
Early results of irradiated homografts have been discouraging, with calcifi cation and 
degeneration often within the fi rst year (2, 22). Instead there has been an increasing 
use of fresh and cryopreserved grafts because of better results and increased avail-
ability from valve banks (23, 24).
Biological conduit valves
Biological valves are manufactured from porcine or bovine pericardium, porcine aor-
tic valve, or bovine jugular veins. The vascular tube is often constructed from synthet-
ic material. Various valves are available from several manufacturers. The Hancock® 
bioprosthetic valved conduit (Medtronic) is a commonly used conduit consisting of a 
?? ?? ??
Indications for intervention after repair of tetralogy of Fallot Class Level
PVR should be performed in symptomatic patients with severe PR and/or  1 C
stenosis (RV systolic pressure >60 mmHg, TR velocity >3.5 m/s) 
PVR should be considered in asymptomatic patients with severe PR and/or PS  2a C
when at least one of the following criteria is present: 
• Decrease in objective exercise capacity 
• Progressive RV dilatation 
• Progressive RV systolic dysfunction 
• Progressive TR (at least moderate) 
• RVOTO with RV systolic pressure >80 mmHg (TR velocity >4.3 m/s) 
• Sustained atrial/ventricular arrhythmias 
Indications for intervention in patients with right ventricular to 
pulmonary artery conduits 
Symptomatic patients with RV systolic pressure >60 mmHg (TR velocity >3.5  1 C
m/s; may be lower in case of reduced flow) and/or moderate/severe 
PR should undergo surgery 
Asymptomatic patients with severe RVOTO and/or severe PR should be  2a C
considered for surgery when at least one of the following criteria is present: 
• Decrease in exercise capacity (CPET) 
• Progressive RV dilatation 
• Progressive RV systolic dysfunction 
• Progressive TR (at least moderate) 
• RV systolic pressure >80 mmHg (TR velocity >4.3 m/s) 
• Sustained atrial/ventricular arrhythmias 
Table 1. Summary of ESC guidelines from 2010, including indications for PVR after repair 
of TOF and reintervention of RV-PA conduits. Class, class of recommendations; Level, level 
of evidence; RVOTO, right ventricular outfl ow obstruction; TR, tricuspid valve regurgitation
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porcine aortic valve with a woven fabric conduit. The Contegra® pulmonary valved 
conduit (Medtronic) is derived from bovine jugular vein with three leafl ets. It is pre-
served in glutaraldehyde and rinsed in isotonic saline before surgical implant, and 
comes in sizes up to a maximum of 22 mm. There are also conduits mounted on a wo-
ven polyester conduit (Dacron) such as the Carpentier-Edwards bioprosthetic valved 
conduit (Edwards Lifesciences), in sizes from 12 to 30 mm. Contemporary analysis 
from 1992 to 2008 showed no difference in reintervention rates between porcine and 
pericardial valves (25).
In a recent report from Sweden the conduit RVOT Elan™ (Vascutek, Renfrewshire, 
UK) porcine stentless valve and a vascular graft demonstrated excellent short-term 
performance (26).
Mechanical valves
Mechanical valve prosthesis is another alternative for PVR in CHD. The success of 
this method, however, is limited because of the risk of valve thrombosis, especially 
in patients with severe RV failure. Anticoagulation with warfarin plus antiplatelet 
therapy is often needed (27, 28). This method can be used in selected patients with 
concomitant indications for anticoagulation.
Comparison of homograft and other conduits
In a review of outcomes after PVR in patients with TOF, the authors concluded that 
there is confl icting evidence as to whether homografts or xenografts have the best 
results (18). Studies are often matched comparisons, and historical controls and ran-
domized trials are lacking. There are studies of mainly children indicating that xe-
nografts are superior to homografts (29-32), but also reports stating that homografts 
have better long-term durability than xenografts in children (33, 34). In one study the 
Contegra xenograft was superior to homograft and porcine xenograft in children but 
was implanted in the most recent era, which may have had some impact on the results 
(29).
In a large cohort of 293 homografts and 54 Contegras mainly in children and adoles-
cents, the authors found three independent risk factors for graft replacement: graft size 
≤20 mm, nonanatomical position, and Contegra conduit. The main reason for dys-
function of the Contegra conduit was stenosis of the distal conduit anastomosis. Ten-
year freedom from graft replacement was 81.4% in the homograft group and 63.5% 
in the Contegra group (35). Another study comparing xenografts and homografts also 
found more supravalvular stenosis in the xenograft group (36).
Nonhomograft conduits have been associated with an increased risk of hemodynamic 
conduit dysfunction in adults (37). There are no studies of adults that show superiority 
of xenografts over homografts.
Factors infl uencing conduit durability
Studies have identifi ed a number of risk factors for reduced conduit durability and re-
operation. Data are predominantly from studies of pediatric patients or mixed cohorts 
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of infants, children, adolescents, and adults. Both congenital right heart malforma-
tions and Ross-operated aortic valve disease are often included in the studies.
Young age is a dominant risk factor for conduit failure, especially in younger age 
groups (30, 32, 33, 38-44). Furthermore, diagnosis and anatomy are important. Sev-
eral studies show that conduit implantation in a nonanatomical position (such as trun-
cus arteriosus) performs worse, than for example TOF, whereas Ross-operated aortic 
valve disease seems to experience the best outcome (29, 30, 33, 35, 42, 45-47). A 
smaller size of conduit is associated with reduced longevity but is related to young 
age and diagnosis (33, 43, 46). Oversizing of valves, however, is not associated with 
increased longevity (48). Among patients with a conduit, conduit size appears to be 
correlated with age. Adult sizes are implanted after approximately 8 years of age (15, 
46). For homografts, some reports indicate that aortic grafts perform worse than pul-
monary grafts in the RV-PA position in children (24, 40, 43, 44, 49). Similar conclu-
sions have been reached in several studies of mainly adolescents and adults (41, 45, 
50, 51). However, reports that do not confi rm these fi ndings also exist (52).
Pediatric studies indicate that implantation of a homograft is associated with systemic 
infl ammation (53), and this has led to studies on blood group and HLA compatibility. 
There are reports that HLA or ABO mismatch in young children could lead to earlier 
graft failure and calcifi cation (38, 50, 54), although others do not confi rm this fi nding 
(34, 55). Neither has treatment with azathioprine after implantation of cryopreserved 
homografts showed reduction of immune response to HLA alloantigens or improved 
graft function in a prospective randomized trial of 13 children (56). However, post-
operative prophylaxis with ibuprofen has been associated with improved longevity of 
homografts in children (Travelli et al., Abstract at ACC 2015).
Explanted homografts demonstrate changes in cellularity and infl ammation (57), and 
implantation of homografts has been associated with postoperative systemic infl am-
matory response (53). Furthermore, HLA or ABO incompatibility has been associated 
with graft calcifi cation and worse early outcome in some reports (38). This has led 
to the development of a decellularized homograft to reduce cellularity, called Syner-
Graft® (Cryolife Inc.) (58). Short-term results of the cryopreserved decellularized 
homograft indicate a decreased immunologic response, but limited hemodynamic ad-
vantage and no reduced rate of reintervention in comparison with conventional homo-
grafts (59, 60). However, decellularized fresh homografts seem to have better durabil-
ity than cryopreserved homografts and xenografts in a matched comparison, although 
the cohort size was limited to 38 patients per group (61). There was also a tendency 
for adaptive growth of the decellularized grafts.
Early hemodynamic defects on echo or magnetic resonance imaging (MRI) have been 
associated with reduced longevity (32, 62, 63). Patients with TOF without early post-
operative PS or PR are unlikely to have homograft dysfunction or replacement within 
10 years (64).
Recent reports of adults and adolescents indicate that a high body mass index and 
smoking are associated with conduit dysfunction (37, 39). One possible explanation 
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for this fi nding is mediation via systemic infl ammation, which previously has been 
associated with atherosclerosis.
Regarding outcomes after conduit replacement (surgical conduit reinterventions), re-
ports have not conclusively stated an association with reduced or improved longev-
ity compared with the fi rst conduit. Studies imply that conduit longevity is equal (or 
better) at reoperation (15, 46, 62). However, Buber et al. concluded that placement of 
conduits before index surgery represented a risk factor for conduit dysfunction in their 
cohort of adults undergoing conduit surgery (37).
Transcatheter pulmonary valve replacement
In Sweden, TPVR has been available for the treatment of conduit failure since 2007. 
Sahlgrenska University Hospital/Östra started using this method in adults in Janu-
ary 2008. In 2009, the Health Technology Assessment Center in Gothenburg made 
an assessment of this method and concluded that TPVR seems less inconvenient for 
the patient in comparison with surgery but that long-term data and comparisons with 
conventional surgery are lacking. The most widely used valve for TPVR in Sweden is 
the Melody® valve (Medtronic), although in other cases the Edwards SAPIEN valve 
(Edwards Lifesciences) has been used.
The Melody valve is a stent-mounted bovine jugular vein expandable to 18–22 mm. 
Indications for use are in postsurgical RVOTs with a conduit (>16 mm) or bioprosthe-
sis. Contraindications for implantation are no central venous access, conduit dimen-
sion >22 mm, or proximity to coronaries with risk of compression. In 2000, Bonhoef-
fer et al. described the fi rst successful implantation of a transcatheter pulmonary valve 
(65). This introduced a new way of managing patients with dysfunctioning RV-PA 
conduits that were previously treated with percutaneous stents or reoperation for re-
placement of the conduit. There are now data from up to 7 years of follow up with the 
Melody valve after TPVR in obstructed or regurgitant conduits (66). Technical suc-
cess is approximately 90% in several studies. Sustained hemodynamic improvement 
has been reported, with low gradients and reduction in PR with subsequent reduction 
in RV volume (66, 67). Five-year freedom from reintervention and explant were 76% 
and 92%, respectively (66). Stent fractures requiring reintervention were common in 
the early experience, but have become infrequent since the advent of pre-stenting. 
Valve in valve is reported to be feasible in selected patients. Coronary compression 
was the main reported cause of perioperative mortality, with an occurrence rate of 
1% (67). Conduit rupture is also a known complication (68, 69). In a cross-sectional 
registry study in the United States, the most common complications were vascular 
related, in 14% of the patients. The risk of death was 1.7%, and 3.5% needed open 
heart surgery (70, 71) (Figure 4).
There are also reports on short-term follow up of the Edwards SAPIEN valve in dys-
functional conduits (72). The technical success for this valve was 97% in this small 
study of 36 patients. The advantage of this valve is that it is available in larger sizes of 
23, 26, and 29 mm (SAPIEN XT), making it potentially feasible for dilated conduits. 
A positive hemodynamic and clinical outcome at 6 months was reported on conduits 
16–24 mm in size.
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Figure 4. Implantation of the Melody valve in a RV to PA conduit . Valve delivery, 
preexpansion (on top). Valve implanted (below). Courtesy of Medtronic.
There are reports on the use of both Melody and Edwards in small conduits (<16 mm) 
and nonconduit or postsurgical native RVOTs (73, 74). Implantation in postsurgical 
conduit-free RVOT has been shown to be feasible in a two-step procedure whereby 
valve implantation is preceded by a bare-metal stent 2 months earlier, creating a land-
ing zone of <24 mm for the valve (74).
Several reports on the increased risk of endocarditis after TPVR have raised concerns 
for the long-term outcome of the Melody valve. The incidence of endocarditis was 5% 
over 2.5 years of follow up (75). A retrospective study concluded that both the Melody 
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valve and the Contegra conduit have an increased incidence of infectious endocarditis 
(7.5% at 2 years) compared with homografts (2.4% at 6 years) (21).
Development of new and improved devices for large or native RVOTs is ongoing. The 
self-expanding Venus P valve has recently been presented as an alternative in patients 
with TOF and previous transannular plasty or dilated conduit (76).
Long-term results
Short- and long-term mortality
Perioperative mortality is approximately 1% in adults after conduit surgery (37). In a 
meta-analysis of children and adults subject to PVR (including conduits), the pooled 
30-day mortality was less than 1% while the 5-year mortality and redo PVR were 
2.2% and 4.9%, respectively (77). TPVR is reported to have a perioperative mortality 
of 1% (67).
The long-term mortality after conduit surgery in adults is not negligible, with survival 
rates of 87% and 81% at 10 and 15 years’ follow up, respectively (37). In a study of 
mainly children from the early surgical era, 10- and 20-year survival rates were 77% 
and 59%, respectively (30), excluding perioperative mortality. Long-term survival 
after TPVR was 98% at 5 years (66).
Event-free survival and need for reintervention
Large cohort studies of patients with conduits are predominantly of children with vari-
ous malformations, and show an event-free survival of 82%–84% and 55%–58% at 
5 and 10 years, respectively (30, 33). In adults (median age 19 years) with a conduit 
larger than 18 mm at implantation, Buber et al. found an event-free survival of 95% 
and 81%, respectively, at 5 and 10 years. The probability of survival without hemody-
namic conduit dysfunction was even lower, with a 5- and 10-year probability of 87% 
and 63%, respectively, indicating that hemodynamic dysfunction is common and pre-
cedes the need for conduit reintervention (37). Adult patients with aortic valve disease 
operated with Ross procedure seems to have the best outcome, with more than 90% 
freedom from conduit reintervention or replacement after 15 years (78). For TPVR, 
5-year freedom from reintervention and explant was 76% and 92%, respectively (66).
Effect of PVR on right ventricle size and function
It has been known for a long time that PVR after PR reduces RV volume (79). There 
are also well-recognized reports that wide QRS duration is related to RV size and pre-
dicts malignant ventricular arrhythmias, and electrophysiological data showing that 
RV volume and pressure overload are associated with inducible sustained ventricular 
tachycardia (VT) (80, 81). Moreover, there is evidence of a clinical relationship be-
tween PR and ventricular arrhythmia and sudden death (82). Further reports conclude 
that a volume-overloaded right ventricle and ventricular functional impairment pre-
dict an adverse outcome (83). There are also mechanistic reports concluding that RV 
overload with a dyskinetic RVOT leads to conduction delay, bundle block, and further 
RV dysfunction (84).
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MRI for the measurement of ventricular volume, function, and techniques for measur-
ing fl ow has since its introduction become increasingly available, and is now routinely 
used in the clinical follow up of these patients. The main surrogate outcome variables 
after PVR are reduction in RV volume and improvement in systolic function. Mea-
surement of pulmonary fl ow (regurgitation fraction) can also be of value. Data indi-
cate that operating before systolic function deteriorates is positive for postoperative 
RV function (85). Moreover, several studies indicate a preoperative threshold above 
which RV volume as measured by MRI will not recover to normal after PVR. This 
threshold is between 150 and 170 ml/m2 RV end-diastolic volume (RVEDV) (86-89) 
and 80 ml/m2 RV end-systolic volume (88, 90, 91). Above this threshold there is a risk 
that the point of no return is reached. These data seem to have started a trend toward 
a more proactive approach to PVR, and this is refl ected in ESC guidelines (10). How-
ever, confl icting reports exist. In a matched comparison, Quail et al. concluded that 
there is no volumetric cutoff and that progression of disease is slow (92).
The impact on PVR can also extend beyond the right ventricle, since there are reports 
of improved left ventricular function after PVR in patients with TOF. Moreover, such 
improvement was related to pre-PVR RVEDV (93). 
It has been speculated that changes preceding impaired RV function and increased 
size are of importance, since patients developing PVR at a younger age have better 
outcomes despite recovery of RV function after PVR (87). For example, there is evi-
dence of ventricular fi brosis in patients with CHD and TOF (94, 95).
Given the available data, therefore, one may well ask whether we are studying the 
appropriate surrogates. There are studies of various other variables such as RV output 
power measured by MRI (96) and deformation imaging that predicts postoperative 
ventricular function and functional class (97).
Frigola et al. studied adult survivors after initial correction but not subjected to further 
PVRs. They concluded that this group has normal RV ejection fraction and only mild 
dilation of the right ventricle, with a mean RVEDV of around 100 ml/m2. Mild RV 
outfl ow obstruction was common, and exercise capacity was near the normal refer-
ence (98). The authors concluded that many patients with simple TOF (mild pheno-
type) who have had early initial repair may not be in need of PVR even over the longer 
term. This study highlights the variations in outcomes in this group of patients.
Effect of PVR on quality of life and exercise capacity
Patients with CHD are known to have reduced exercise capacity. Multiple factors be-
sides the actual CHD infl uence exercise capacity, for example lung function. Among 
patients with CHD, reduced peak oxygen consumption (peak VO2) identifi es patients 
at higher risk of hospitalization or death (99). However, patients with TOF and severe 
PR can preserve exercise capacity for a long time despite RV dilatation (100). It is also 
reported that restrictive RV physiology predicts superior exercise performance (101). 
High preoperative peak VO2 at cardiopulmonary exercise testing has been shown to 
predict early surgical outcome in adults with TOF after PVR (102).
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Studies of surgical PVR in patients with TOF and PR indicate limited effect on peak 
VO2 after PVR. There was, however, an improvement in the ventilator response to 
carbon dioxide (VE/VCO2) at anaerobic threshold, with the best results in the young-
est patients (87, 103). In studies of TPVR there are reports of improved peak VO2 
after TPVR (104). Reduction of the RVOT gradient is a predictor of improved peak 
VO2 (105) indicating the effect of TPVR primarily in patients with PS. In other studies 
improved VE/VCO2 has been reported after Melody PVR, but with no improvement 
in peak VO2 (66, 106).
Several studies have shown an improvement in New York Heart Association (NYHA) 
functional class and symptoms after surgical PVR or TPVR (66, 69, 87, 103, 107, 
108). There are also reports on improved quality of life (QoL) (Short-Form 36-Item 
Health Survey; SF-36) after TPVR (104). Furthermore, postoperative QoL (SF-36) 
has been found to be comparable with that of the general population after surgical 
PVR (41).
There are discussions regarding why there seems to be an improvement in symptoms, 
NYHA class, and VE/VCO2 slope, but not peak VO2, after PVR and TPVR. One sug-
gestion is that patients breathe more easily after PR is relieved, which could improve 
ventilator effi cacy. There are, however, many factors besides PR and PS that affect 
exercise capacity, such as pulmonary dysfunction at spirometry (66).
Effect of PVR on arrhythmia and survival
Studies on the effect of PVR on arrhythmia and survival are mainly from observation-
al studies of patients with TOF. Gatzoulis et al. reported a 2% risk of sudden cardiac 
death over 8 years of follow up in a landmark study of patients with TOF. Wide QRS 
and PR as a dominating hemodynamic lesion was considered to be associated with 
an increased risk for VT or sudden death (80, 82). There are also reports of increased 
mortality risk from pulmonary stenosis (109). Furthermore, increasing RV size is 
found to be related to death or VT (83). Longitudinal left ventricular function also 
seems to be associated with sudden cardiac death and life-threatening arrhythmias 
in patients with TOF (110). Moreover, RV hypertrophy and reduced right or left ven-
tricular function, as well as supraventricular tachycardia, have been associated with 
death and VT. Valente et al. conclude that prolonged PR or PS may be risky (109). 
Since PVR has been associated to some extent with reduction of QRS width (111), 
there are hopes that PVR can improve survival and reduce the risk of sudden death. 
However, the impact of PVR on arrhythmia and survival in the advanced stages is 
disappointing. Despite normalization of RV volume and a positive effect on symp-
toms and functional class, there are observations suggesting no survival benefi t or no 
reduced risk of malignant arrhythmia in a matched comparison, albeit the analysis is 
limited by low incidence (103). Another study concluded that PVR had no impact on 
survival and VT in a comparison with matched controls; neither was there narrow-
ing QRS after PVR. However, there were differences between the PVR and control 
groups regarding RV size and function at baseline, where the PVR group had a signifi -
cantly larger right ventricle (112).
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VT ablation has no signifi cant impact on arrhythmia-free survival after PVR (113). 
However, there are reports of a positive effect on post-PVR atrial and ventricular 
arrhythmias when combining PVR with cryoablation in patients with pre-existing 
arrhythmias (114). Furthermore, the benefi t of surgical RVOT remodeling has been 
studied in a randomized trial of resection of the noncontractile aneurysm in RVOT, 
with no signifi cant effect on early outcomes (115).
Summary of timing and effects of PVR
The current assumption for the management of PVR may be summarized as: “PR 
leads to RV dilatation and RV dilatation is associated with adverse outcomes. Thus, 
PVR to eliminate PR, reduce RV volume, and improve RV function should prevent 
bad outcomes.” However, to date there is no evidence that earlier PVR leads to re-
duced risk of malignant arrhythmias or death. Therefore, the optimal timing for PVR 
is yet to be determined. 
In conclusion, no study to date has shown reduced mortality after earlier PVR. How-
ever, there are multiple reports on reduction of RV size and improved RV function 
after PVR. The risks of repeated operations should therefore be set against the risks 
of irreversible RV failure, arrhythmia, and death. There is evidence to indicate that 
surgical PVR or TPVR leads to improved NYHA functional class, QoL, and, to some 
extent, improved exercise capacity.
Quality of life and health outcome
More children born with CHD are living through adolescence and adulthood (9). With 
increasing survival there is an increasing interest not only in studying surgery and care 
but also the patients´ QoL. There is, however, no universal defi nition of QoL, which 
makes measurement problematic and limits the validity of studies (116). Tools for 
measuring QoL have changed over time. In early studies NYHA functional class, em-
ployment, and symptoms were commonly used as surrogates for QoL. Over the years 
validated instruments such as the SF-36 or EQ-5D have increasingly been employed 
(117), although there is no consensus concerning the optimal instrument for measur-
ing QoL. When studying QoL in individuals with a disease, the term health-related 
QoL (HRQoL) is used to highlight that QoL is affected by the impact of the disease 
or treatment on the patient’s physical, psychological, or social functioning accord-
ing to Bowling et al. Since CHD is a chronic condition sometimes accompanied by 
lifelong impairment, QoL and HRQoL are key outcome measures (118). Furthermore, 
there is a need for longitudinal and interventional studies, since these are very rarely 
conducted (119). QoL in patients with CHD has been reported to be equivalent to (or 
better than) that of the general population (120, 121), although there are confl icting 
reports on this matter (122). A study from Sweden shows a correlation between symp-
toms, age, NYHA class, and female gender, and poorer health outcome (EQ-5D). Fur-
thermore, 20% of the patients who considered themselves asymptomatic still reported 
problems with pain/discomfort and anxiety-related depression. These fi ndings should 
encourage health care providers to actively ask the patients about their symptoms and 
well-being (123). 
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Little is known about QoL in patients with previous RVOT surgery or conduits. There 
are reports on improved QoL after TPVR in accordance with increasing SF-36 scores 
(104). QoL late after surgical PVR has been studied (41). Patients scored lower on 
physical functioning and general health in comparison with the general population, 
although no longitudinal analysis was carried out.
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AIMS
Overall aim
To study QoL, trends of treatment and survival, event-free survival, and the need for 
reintervention in adults with a conduit, using the SWEDCON/GUCH registry.
Specifi c aims
Paper I   to report outcomes after surgical RVOT reconstruction with a homo-
graft as described in the scientifi c literature.
Paper II   to examine longitudinal self-reported health measured by the EQ-5D 
questionnaire in patients with previous RVOT surgery.
Paper III  to investigate trends of implantation of conduits (new and reopera-
tion) and TPVR over a 15-year period; whether the introduction of 
TPVR has led to a reduced need for conduit surgery; and the impact 
of age, diagnosis, and the longevity or number of previous conduits 
on deciding between surgical replacement and TPVR.
Paper IV   to examine survival, event-free survival, and predictors of survival in 
patients with a conduit after a fi rst conduit operation and after conduit 
reintervention.
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PATIENTS AND METHODS
Ethics
This study was approved by the regional board of ethics and the board of directors 
of the SWEDCON registry. The study complies with the World Medical Association 
declaration of Helsinki Ethical Principles for Medical Research Involving Human 
Subjects.
SWEDish registry of CONgenital heart disease (SWEDCON)
Both adult and pediatric cardiology and cardiac surgery have had several local regis-
tries dating back as far as the 1980s. A nationwide Swedish registry of adult patients 
with CHD called “GUCH-registret” was created in 1998. These data were later in-
corporated into the SWEDCON registry in 2009 when adult and pediatric CHD was 
merged into one nationwide database. A Web-based platform was created in 2005 in 
collaboration with Uppsala Clinical Research Center (UCR). SWEDCON has four 
parts: fetal cardiology, pediatric cardiology, SWEDCON/GUCH (adult CHD), and 
congenital heart surgery. Inclusion criteria in SWEDCON/GUCH are: care at a clinic 
participating in SWEDCON, CHD, and ≥16 years of age. All parts of the registry 
share the same baseline characteristics regarding birth date, diagnosis (ICD), surgery, 
pacemaker implantations, and percutaneous interventions for surgical procedures. 
Group variables help to identify relevant groups of patients, for example, patients 
with a RV-to-PA conduit. Each part of the registry also has a specifi c dataset created to 
meet its specifi c needs. There are data regarding gender, marital status, employment, 
education, and smoking. Physiological data such as ECG, echocardiography fi ndings, 
blood tests, and medication are also included as well as physical functional status 
according to the NYHA classifi cation scored by the cardiologist or nurse. Further-
more, symptoms reported by the patients and physical activity are documented in the 
registry. Patient-reported outcome measurements (PROM) are included. Since 2005, 
health outcome has been reported using the self-administered questionnaire EQ-5D.
Since 2008 congenital heart surgery of both children and adults has been performed 
in two centers, Lund and Gothenburg, covering the entire Swedish population. TPVR 
is currently performed in three centers, namely Gothenburg, Lund, and Stockholm. 
All seven university hospitals have been covered by the registry since 1998: Aka-
demiska sjukhuset Uppsala, Karolinska universitetssjukhuset Solna, Norrlands uni-
versitetssjukhus Umeå, Skånes universitetssjukhus Lund/Malmö, universitetssjukhu-
set Linköping, universitetssjukhuset Örebro, and Sahlgrenska universitetssjukhuset/
Östra Göteborg. There are also GUCH units at several other hospitals covered by 
the registry: Falun, Gävle, Halmstad, Jönköping, Kalmar, Karlskrona, Karlstad, Kris-
tianstad, Skövde, Sunderbyn, Sundsvall, Södersjukhuset, Växjö, and Östersund. Cov-
erage for pediatric cardiology is even broader.
Input of data was in the beginning only implemented by the seven university hospitals. 
Over the last years input has also been done by GUCH units at an increasing number 
of local hospitals. Data input is done in several ways. Patients transferred from pediat-
ric to adult care have their data transferred at the fi rst visit as adults. Patients included 
31
in the registry as adults are included in the registry after informed consent, and have 
their historical data entered retrospectively. The two national centers for congenital 
heart surgery carry put their data input at the date of surgery. Older or missing data 
are entered at follow up visits at the GUCH center or GUCH unit. Efforts have been 
made to catch up with input of older data. SWEDCON is different from many other 
registries in that data input is longitudinal with no defi ned end. Other quality registries 
often include patients after a specifi c event and then follow the patients for a prespeci-
fi ed time period.
In the yearly report from 2014, 11 313 patients were included in the registry. Accord-
ing to demographic data (124, 125) there are likely around 30 000 adult patients with 
CHD in Sweden, leaving the coverage rate at 30% compared with around 20% 5 years 
ago. According to the SWEDCON 2014 annual report, there has been an increase in 
the number of patients in the registry from 4152 patients in 2004 to 11 313 patients 
in 2014. There has been a yearly increase of approximately 1000 patients per year in 
recent years. Data quality assessment is being performed in 2015, but results are not 
available at the time of writing.
SWEDCON is funded by the Swedish association of local authorities and regions 
(SKL, Sveriges kommuner och landsting) and the national board of health and wel-
fare (SoS, Socialstyrelsen). The purpose of the registry is to assess the quality of care, 
surgery, or percutaneous intervention, and to distribute data for scientifi c research and 
Swedish national guidelines. The website is www.ucr.uu.se/SWEDCON.
EQ-5D questionnaire
EQ-5D is a generic instrument used to evaluate health perception and status, compris-
ing two parts: the EQ-VAS and EQ-5D-3L. The EQ-VAS consists of a 20-cm-long 
vertical visual analog scale ranging from 0 to 100. The patient is asked to grade his or 
her general health state, where 100 (on the top) is the best imaginable health state and 
0 is the worst imaginable health state. EQ-5D-3L is a scoring system for fi ve dimen-
sions of health: mobility, self-care, usual activities, pain/discomfort, and anxiety/de-
pression. Each dimension has three levels: no problems, some problems, and extreme 
problems. The score obtained from each dimension can then be combined to a fi ve-
digit number that can be converted into a single summary index using an index tariff. 
An index value of 1 represents full health, and 0 corresponds to death. The validated 
self-administered questionnaire EQ-5D was developed by the EuroQoL group in 1990 
and is applicable to a number of health conditions (126, 127).
In 2014, EQ-5D was used in more than 40 Swedish quality registries that use patient 
reported outcome measures (www.promcenter.se). It has been used in SWEDCON 
since 2005 to measure health outcomes. According to the PROM center, EQ-5D is 
considered to measure HRQoL and is often used together with other instruments, but 
recently on its own, preferably in health economy to calculate quality-adjusted life 
years. EQ-5D is not disease-specifi c. A standard set of sociodemographic questions 
is provided with the questionnaire. Other disease-specifi c PROM are available, how-
ever, including for example CAMPHOR, used in pulmonary hypertension registries.
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Methodological considerations and validity
As SWEDCON has not been subject to a formal study of internal validation, a vali-
dation study of diagnosis, date of surgery, and surgical code is included in Papers 
3 and 4. Internal validity regarding mortality is via the cause of death registry, and 
should therefore be close to 100%. Patients who moved abroad are the only patients 
not covered by death registry. Regarding external validity, there was a concern that 
the expansion of the registry is still ongoing and coincides with the present studies. 
Estimated patient coverage is approximately 30% according to SWEDCON, which 
raises some concern about the external validity of the registry. Coverage of university 
hospitals (n=7) and tertiary centers (n=3), however, is 100% since 1998. Since com-
plex patients or patients in need of surgery or percutaneous reinterventions are given 
care at these hospitals, coverage is estimated to be substantially better than 30% in 
this group. External validity and, thus, generalizability of the results should therefore 
be adequate. All patients in need of RVOT surgery or TPVR are discussed in multidis-
ciplinary conferences in one of the tertiary centers, which should limit selection bias 
for choosing surgery or TPVR.
Evaluation of literature
Paper 1 is a systematic review of outcomes after surgical RVOT reconstruction with 
a homograft in adult patients with CHD. With the assistance of a qualifi ed librarian, 
a search was performed in PubMed and the Cochrane database from their inception 
to May 2012. The search term in the PubMed NLM catalog Medical Subject Head-
ing (MeSH) database was “homograft OR homografts AND pulmonary valve.” The 
search was repeated in May 2015 also including the term “allograft.” This process 
identifi ed 665 articles, of which 133 were retrieved after screening of abstracts and 
cross-check of reference lists to full paper review by two authors. For reporting we 
used the proposed guidelines from the “Meta-analysis Of Observational Studies in 
Epidemiology (MOOSE) group” (128).
Study population
In Papers 2–4, data were collected from the SWEDCON/GUCH registry. Data in 
Paper 2 were collected in December 2012. After completion of Paper 2 a new, more 
specifi ed data collection was performed in April 2015. These data were used for Pa-
pers 3 and 4.
Paper 2 is a retrospective longitudinal cohort study of patients with previous RVOT 
surgery identifi ed by codes for classifi cation of surgical procedures.
Paper 3 is a retrospective longitudinal study of patients with a conduit identifi ed by a 
group variable specifi c to RV-to-PA conduits.
Paper 4 is a retrospective cohort study of patients with a conduit identifi ed by a group 
variable specifi c to RV-to-PA conduits.
In Papers 2–4, all patients were extracted from SWEDCON/GUCH; i.e., they were at 
least 16 years of age and had at least one visit to a GUCH unit. ICD coding was used 
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for classifi cation of diagnosis in all three papers. In Paper 2, the NOMESCO classi-
fi cation of surgical procedures (http://www.nordclass.se/NCSP_1_16.pdf) of surgical 
codes associated with RVOT surgery was used to identify patients. In Papers 3 and 4, 
classifi cation of surgical procedure codes was used as well as a registry-specifi c group 
variable to identify patients with an RV-to-PA conduit.
Statistics
Paper 2. Descriptive statistics were used for demographics and baseline data, and to 
display frequencies in the EQ-5D data. The Wilcoxon signed-rank test was used for 
repeated-measures analysis of EQ-VAS, and a Poisson regression model was used for 
analysis of EQ-5D and EQ-VAS between-groups data. A value of P<0.05 was con-
sidered statistically signifi cant. All statistical analyses were performed with SAS 9.3 
software (SAS Institute Inc., Cary, NC). All statistical analysis was performed in close 
cooperation with and under supervision of a biostatistician.
Paper 3. Descriptive data are expressed as mean, median, and range, as well as fre-
quencies and percentages where applicable. Data are presented for the entire study 
period 2000–2014, and also for the three equal time periods 2000–2004, 2005–2009, 
and 2010–2014, to study the trends regarding interventions. The yearly number of 
surgical procedures and TPVRs were compared across time periods using analysis of 
variance (ANOVA). Post hoc testing was performed with Tukey’s honestly signifi -
cant difference test in conjunction with ANOVA. Changes in characteristics between 
time periods were evaluated using the Kruskal–Wallis test and Chi-square test for 
continuous and categorical variables, respectively. To evaluate continuous variables 
regarding the treatment groups (new implantation, surgical conduit replacement, and 
TPVR), the Kruskal–Wallis test was used to compare all three groups, and the Mann–
Whitney U test was used for pairwise comparisons. The Chi-square test was used for 
categorical variables except when predicted cases per cell were fewer than 5, when 
Fisher’s exact test was used. A P value of less than 0.05 was considered statistically 
signifi cant. All statistical analyses were performed after counsel with a biostatistician.
Paper 4. Continuous and categorical data are presented as counts, percentage, mean, 
and median when appropriate. Cumulative survival and cumulative event-free sur-
vival were determined by the Kaplan–Meier method. Event-free survival was defi ned 
as time from conduit operation to reoperation, TPVR, death, or censor. Point esti-
mates are presented as percentage and standard error (SE). Comparison of survival 
and event-free survival for different groups of diagnosis was performed using the 
log-rank test. Multivariable Cox regression was used to identify predictors of survival 
and event-free survival, and is presented with hazard ratio (HR) and 95% confi dence 
interval (CI). Age was set as an independent variable, and diagnosis group and gender 
were factors. All statistical tests were two-sided, and a P value of less than 0.05 was 
considered statistically signifi cant. All statistical analyses were performed in close 
cooperation with and under supervision of a biostatistician.
Statistical analysis for Papers 3 and 4 was done using SPSS (version 20; SPSS Inc., 
Chicago, IL).
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SUMMARY OF RESULTS
Paper 1
The PubMed database and Cochrane library was searched in May 2012 and once 
again in May 2015, with the terms “homograft AND pulmonary valve” and “allograft” 
generating 665 hits. Only studies of patients with right heart malformations involv-
ing more than 50 patients with a mean or median age >18 years were included. Six 
studies with a cumulative total of 560 patients were ultimately included in the study. 
Perioperative mortality was 0%–2.9%. Long-term mortality was 2%–8.8% at 8.1–10 
years. Reintervention of homografts were common during patients’ lifespans, with a 
10-year event-free survival of 78%–80%. Early postoperative echocardiographic or 
MRI defects appear to predict rapid homograft degeneration (Figure 5, Table 2).
Articles?
identified from?litterature search
(n=665)
Articles?identified from?screening?
of abstracts?(n=110)
Articles?included in??systematic?
review (n=6)
Cross?check?of reference lists?
Articles?to full?paper?
review(n=133)
Figure 5. Illustration of the article selection process in Paper 1.
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Publication author 
year, (n) 
Early
mortality
Late
mortality
Event-free 
survival
Hazekamp 2001, (51) 2% 4% at 1.7 yrs
Oosterhof 2006, (158) 2% at 5.1 yrs 78% at 10 yrs 
Troost 2007, (68) 2.9% 9% at 8.4 yrs 79% at 10 yrs 
Nordmeyer 2009, (60) 0% 0% at 3.3 yrs 95% at 3.3 yrs 
Scherptong 2010, (90) 0% 2% at 5.5 yrs 78% at 10 yrs 
v d Woestijne 2011, (133) 1.5% 8% at 8.1 yrs 80% at 10 yrs 
Table 2. Outcome data in included studies, Paper 1
Paper 2
All patients with previous RVOT surgery and EQ-5D data from their fi rst and latest 
visit were included. Among 103 patients (65 male, 38 female), mean age 31 (range 
19–78) years, the diagnoses were: TOF (n=66); truncus arteriosus, transpositions, and 
double-outlet right ventricle (n=23); and Ross-operated congenital aortic valve dis-
ease (n=14). The mean time from fi rst to latest visit was 3 years (range 1–7 years). 
Eighteen patients underwent 26 reinterventions in the observational period from the 
fi rst to latest visit, including 18 operations and percutaneous interventions and eight 
pacemaker implantations and ablations.
Health perception measured by the mean EQ-VAS declined from 84.4 (SD=14.6) at 
the fi rst visit to 78.6 (SD=18.3) at the latest visit, P=0.001. The decline was not ob-
served in patients with reinterventions between the fi rst and latest visit. Low EQ-VAS 
was associated with patient-reported symptoms and NYHA class II–IV. Patient-re-
ported problems in the EQ-5D dimension “usual activities” were more common in the 
patients having reinterventions (25%) than those without reintervention (7%), P=0.04 
(Figure 6).
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Figure 6. Longitudinal EQ-VAS for patients with no reinterventions (n=85) and with reinter-
ventions (n=18) between the fi rst and latest visit.
Longitudinal EQ-VAS (mean)
36
Internal validation of Papers 3 and 4
Internal validity was assessed by randomly selecting 50 patients with conduit in 
SWEDCON, and data regarding main diagnosis, surgical codes, and date of the last 
surgical procedure were compared across patient charts. Seven missing or false data 
were found in fi ve patients, one (2%) regarding the main diagnosis and three (6%) for 
surgical code and date of surgery, respectively. Thus the overall validity was 95%.
Paper 3
From 2000 to 2014 there was an increase in adult patients with conduits included 
in SWEDCON/GUCH, from 122 to 536. There were 60 surgical conduit replace-
ments, 40 TPVRs, and 176 new conduit implantations in the study period. Periopera-
tive mortality was <1%. The yearly number of new implantations and reoperations 
both doubled over the study period. There was a signifi cant increase in new implanta-
tions (P=0.007), surgical conduit replacements (P=0.024), and a combination of sur-
gical replacement and TPVR (P=0.011) across all three time periods. Patients with 
new implantations were older (median age, 32 years) compared with the reoperation 
and TPVR groups (median age, 26 years), with the majority of patients having TOF 
(57%). The majority of conduit reinterventions were surgical, also after the introduc-
tion of TPVR in 2007, with no signifi cant difference regarding diagnosis, gender, age, 
or previous number or longevity of conduits between surgical replacement and TPVR 
(Figure 7, Table 3).
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Figure 7. Number of surgical conduit re-
placements and TPVR per year in the time 
period 2000 to 2014.
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New implantation Conduit replacement TPVR P-value
Procedures, n 176 60 40
mean age yr (median) 35,9 (32) 31,4 (26) 29,1 (26) P=0.001
male, n (%) 107 (61) 43 (72) 23(58) NS 
Previous conduits, n mean (median) 1,5 (1) 1,4 (1) NS 
Conduit mean age at replacement, yr 13,7 (11) 13,6 (14) NS 
TOF, n (%) 101 (57) 21(35) 15(38) P=0.002
Ross, n (%) 21 (12) 4(7) 6(15) P=0.002
Mixed, n (%) 54 (31) 35(58) 19(47) P=0.002
Table 3. Patients’ characteristics by procedure for 2000–2014.  P-value refers to analysis across 
all procedures.
Reintervention
1
Reintervention
2
Reintervention
3
Reintervention
4
Patients, n 176 54 12 3
Mean age at reintervention (median) 19.1 (16.7) 21.7 (17.9) 27 (26) 35 (40) 
TOF, n (%) 65 (37) 17 (31) 6 (50) 1
Mixed CHD, n (%) 101 (57) 37 (69) 6 (50) 2
Ross, n (%) 10 (6) 0 0 0
Table 4. Characteristics of patients with conduit reinterventions
Paper 4
A total of 574 adult patients with a conduit (mean age 36.1 years) were identifi ed in 
SWEDCON/GUCH. The TOF group was the largest (45%). In total, from 1967 there 
were 769 operations and 50 transcatheter PVRs. Mean age at fi rst conduit operation 
was 20.2 years. Long-term survival after the fi rst conduit operation, including ac-
cumulated perioperative mortality (<0.5%), was 93% at 20 years. The most common 
cause of death was cardiac-related. Higher age at fi rst conduit operation was associ-
ated with increased mortality risk. Event-free survival was 77% and 54% at 10 and 20 
years, respectively. Higher age at fi rst conduit operation had a protective association, 
whereas male gender and complex malformations were associated with increased risk 
of further reintervention. Conduit reinterventions were common (n=245), the majority 
being in patients within the group including complex CHD (57%). Mean number of 
conduit operations and conduit reinterventions was 1.4 per patient. Ten-year event-
free survival after the fi rst conduit reintervention (n=176) was 70%, signifi cantly low-
er than after the fi rst conduit operation (P=0.04) (Table 4, Figure 8 and 9).
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566 222 29                         3
176 43                 
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Figure 8. Kaplan-Meier estimated event free survival after fi rst conduit implantation 
separated by diagnosis. (A: TOF, B: Mixed CHD, C: Aortic valve disease.) Log-rank 
P<0.001.
Figure 9. Kaplan-Meier estimated event free survival after fi rst conduit operation (A) 
and fi rst conduit reintervention (B), Log rank P=0.04.
39
DISCUSSION
One of the main fi ndings of this thesis relate to declining health perception in patients 
after RVOT surgery. This decline is almost exclusively seen in patients with no further 
reinterventions in the study period. Other main fi ndings relates to studies of outcome. 
Long-term survival is 93% at 20 years. Event-free survival after conduit or homograft 
surgery is 77% at 10 years, indicating that reinterventions are common. Less than half 
of the reinterventions in adults were TPVRs after its introduction in 2007. Outcomes 
after conduit reinterventions are worse than after the fi rst conduit implantation.
Discussion of the specifi c content of papers is available in each respective paper. This 
is a general discussion of the overall fi ndings of this thesis translated to the patients 
who inspired my interest for this area of research. From the results of this thesis, am I 
now able to answer my own questions from the beginning of my PhD studies, and, it 
is hoped, eventually use this knowledge in my clinical practice?
“Is this a growing group of patients since more patients with CHD are reaching adult-
hood?” 
The number of adult patients with an RV-to-PA conduit is increasing. This affects 
health care providers, since there is an increasing need for conduit surgery or conduit 
reinterventions as well as the number of outpatient visits and imaging scans. Optimal 
timing for PVR is not addressed in this study, but ongoing data in this fi eld will likely 
have a further impact on the future number of conduit operations or reinterventions. 
Besides the increase in the number of adults with complex CHD, improvements in 
cardiac surgery and care in addition to an increased focus on the timing of PVR may 
already have infl uenced clinicians in moving from a reactive to a more proactive ap-
proach (7, 102). Thus, the increased use of conduits late after initial repair for TOF 
can theoretically be linked to less toleration for PR late after TOF repair, leading to a 
more proactive approach. These are possible explanations for the increasing number 
of adults subject to the implantation of conduits. Development of new methods for 
TPVR in both native and large RVOT will likely also have a sizable impact in the 
future.
“What is the impact of TPVR in adults, and is surgery needed less frequently now?” 
The number of surgical conduit replacements has increased despite the introduction of 
TPVR. This tells us that the increase in all conduit reinterventions cannot be explained 
by the introduction of TPVR alone. TPVR could otherwise have been considered less 
invasive, causing a shift in indications for PVR. Neither is the increase in surgical 
conduit reinterventions a result of failing TPVRs, since this rarely occurred. Even in 
the most recent era (2010–2014), more than half of the conduit reinterventions were 
surgical despite increasing recognition for TPVR in failing conduits. Age, diagno-
sis, gender, and the number and durability of previous conduits appeared to have no 
impact on deciding between surgical conduit replacement or TPVR. This suggests 
that the need for concomitant surgery, or anatomical factors such as proximity of the 
conduit to coronary arteries or conduit size, has a greater infl uence on this decision. 
Future expansion of TPVR to nonconduit RVOTs and new devices for various ana-
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tomical settings will have a large impact on the need for surgery. Surgical conduit re-
placements and TPVR in a national perspective has not been studied before. There are 
however reports on increasing numbers of PVR in patients with TOF from registries 
in the United States (12).   
“How is HRQoL affected in these patients, given that conduit reinterventions are 
common?” 
I have met many patients who describe worse HRQoL in periods of worsening symp-
toms and functional impairment. From Paper 2 and study of the literature, I consider 
this likely to be a common problem, since symptoms and NYHA class higher than I 
was associated with worse perceived health according to a lower EQ-VAS score. The 
decline in health perception seen over time could be linked to this fact. Moreover, this 
decline is almost exclusively seen in patients with no further reinterventions. One pos-
sible explanation for this is that symptoms (associated with low EQ-VAS) trigger de-
cisions for reinterventions with the aim of relieving symptoms. There is likely a lower 
threshold for reinterventions in symptomatic than in asymptomatic patients. However, 
what about the impact of reinterventions on HRQoL? The study was not primarily 
designed to answer this question. The small numbers in the study limit the analysis, 
although no improvement after reinterventions was seen. On the other hand, neither 
does reintervention seem to have a negative impact on health perception. Problems 
in the dimension “usual activities,” however, were more common in reintervention 
patients. There was a concern that the fi ndings in Paper 2 might indicate a gender 
bias, since reinterventions were more common in men. Further testing, however, did 
not reveal any gender difference in EQ-VAS score (data not included in this study). 
Further longitudinal studies on how reinterventions and reoccurring symptoms affect 
long-term HRQoL may be of importance. Longitudinal studies on HRQoL in patients 
with CHD are lacking (119). 
“What is the long-term survival in this group and what are the mortality risks of con-
duit reinterventions?” 
The estimated survival 20 years after conduit surgery is more than 90% from a mean 
age of 20 years old. This indicates low, but certainly not negligible, long-term mortal-
ity. Perioperative mortality, however, is low (<1%) even after conduit reinterventions 
which is in line with previous reports (37, 77). This tells us that the accumulated 
perioperative mortality risk of conduit reinterventions in the patient’s lifespan is low 
in relation to total mortality, which is dominated by cardiac-related death. From an 
adult congenital heart cardiologist’s point of view, it is evident that these patients need 
lifetime follow up of their well-being and hemodynamics. The fact that higher age at 
complete correction with a conduit is associated with an increased risk of mortality is 
interesting and worth bearing in mind when addressing these patients. Furthermore, it 
could contribute to the ongoing discussion about the timing of PVR.
“What is the expected event-free survival after conduit surgery?“ 
Conduit reinterventions are common, with nearly half of the patients with a conduit 
being subject to reoperation or reintervention at 20 years’ follow up. Evaluation of 
the literature suggests similar fi ndings. Anatomy and diagnosis has a great impact on 
outcome after conduit operations (30, 33, 42, 45, 46). When studying the event-free 
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survival curves and output from Cox regression, the Ross procedure has event-free 
survival superior to that of TOF. Moreover, the mixed group including complex mal-
formations and nonanatomical position appears to achieve the worst outcome. The 
survival curve after the Ross procedure refl ects the longevity of the conduit under 
optimal hemodynamic conditions, and is almost fl at for 10 years with very few events, 
refl ecting what seems to be the longevity of the actual conduit before it degenerates. 
When anatomy is increasingly complex the event-free survival decreases, refl ecting 
the abnormal hemodynamic situation, for example in nonanatomical positions. There 
could also be kinking of the conduit and compression against the chest wall. Further-
more, TOF and complex lesions often have a malformed right ventricle that might 
already have been exposed to unfavorable hemodynamic conditions such as PS or 
PR. Young age is a dominant risk factor for reintervention especially in younger age 
groups, in both this study and previous reports. The fact that male gender is associated 
with worse outcomes is diffi cult to explain and warrants further analysis.
“Can we expect improved conduit durability in conduit reinterventions, since somatic 
growth may no longer be a limiting factor?” 
Young age is a risk factor for conduit reinterventions in the literature as well as in 
this study (30, 32, 33). In light of the growing population of adults with conduits and 
the fact that conduit reinterventions are common, there is a growing need for data on 
repeated procedures. One of my patients asked me: “Somatic growth is no longer a 
problem. Can I expect increased durability this time?” Unfortunately, this study does 
not confi rm this wish and hope. Previous studies report equal or longer durability at 
reoperations (15, 46, 62). However in Paper 4 the event-free survival is around 70% 
at 10 years after conduit reinterventions, which is signifi cantly lower than that after 
the fi rst conduit operation. Although there are limitations to this analysis, the fi ndings 
do raise concern for the future. If longevity is shorter after conduit reinterventions, 
we will encounter even more often the problem of risk-benefi t calculation for PVR. 
This will demand increasingly complex decisions, and thus calls for new ways of 
managing these patients. There are some possible mechanistic explanations for the 
decreasing durability of the second conduit; for example, immunologically the fi rst 
conduit (homograft) could negatively affect the durability of the second. Another pos-
sible explanation might be refl ected in the Cox regression analysis, which reveals 
higher age at fi rst conduit operation to be associated with higher risk after fi rst conduit 
reintervention. Is this a result of sustained negative effect of late initial correction 
with a conduit? This can be discussed from the model of a patient with TOF. Initial 
repair for TOF is most often to relieve the RV of a RVOT obstruction. As a result 
of the initial repair many patients are left with pulmonary regurgitation. If a patient 
with severe post initial repair PR is operated with a conduit at an older age he/she has 
longer time with volume loading of the RV than a patient operated at a younger age. 
Furthermore, at conduit reinterventions the hemodynamic conditions can be different 
with a degenerated and stenotic conduit. Thus, the previously volume loaded RV is 
now subject to pressure loading. What does these alterations in hemodynamics and 
time with pressure and volume loading mean in a lifetime perspective? Taking initial 
palliation with a shunt into account the situation gets even more complex. Perhaps the 
key to successful reinterventions later in life is a strategy with very little volume or 
pressure loading of the RV in children?
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The main strength of this thesis is its national perspective. All Swedish tertiary centers 
for surgery and TPVR have been included in SWEDCON since 1998. Furthermore, 
a publicly fi nanced health care system limits selection bias from sociodemographic 
causes. Follow up on mortality is close to 100%, since SWEDCON is linked to the 
cause of death registry. Decisions for conduit operations or reinterventions are taken 
at multidisciplinary conferences specifi cally for patients with CHD, limiting selec-
tion bias for surgery versus TPVR. However, the advantages of a large database are 
often associated with a loss of specifi c patient-related data, thus limiting the scope of 
analysis.
Multidisciplinary conference discussions about patients with conduits should be man-
datory. Competencies in congenital cardiac surgery, structural interventions, imaging, 
and congenital cardiology are needed for a structured management plan. Treatment 
strategy should reach beyond initial correction or the current correction, and planning 
for the entire lifespan is warranted. In a multidisciplinary conference it is mandatory 
for those clinicians present to have knowledge of perioperative mortality, long-term 
mortality, and expected event-free survival to enable qualifi ed and accurate decision 
making. Lifetime management of patients with a conduit is a constant balance be-
tween risks and benefi ts of operations or reinterventions while simultaneously taking 
into account the preferences and QoL of patients.
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CLINICAL IMPLICATIONS
This study likely refl ects the results of conduit surgery conducted in prime settings of 
dedicated tertiary centers, providing surgery and care with ready availability, from a 
publicly fi nanced health care system. In this retrospective cohort, long-term mortality 
after conduit surgery is relatively low, and in fact numerically lower than that reported 
in other studies such as by Buber et al. (37). The low long-term mortality is potentially 
the consequence of an active treatment approach over the last decades. Despite a 
signifi cant need for conduit reintervention, in this as well as other studies the accumu-
lated perioperative mortality is low in relation to cardiac-related death. Although this 
is not a mechanistic study, I consider that this fi nding, together with increased mortal-
ity after RVOT reconstruction with a conduit at an older age, supports the benefi ts of 
a proactive approach to PVR rather than a more conservative one.
Since conduit reinterventions are very common, or almost inevitable, our focus should 
be on efforts to improve conduit longevity, thus reducing the need for reinterventions. 
Since anatomy is of importance and early hemodynamic defects seem to predict an 
adverse outcome (Paper 1), special attention should be paid to patients with early 
postoperative hemodynamic defects. Perhaps the focus should already be set in the 
operating room to optimize anatomy and evaluate hemodynamics at a very early stage.
Many centers, including Gothenburg, manage patients with failing conduits accord-
ing to the principle “surgery when necessary, percutaneous when possible.” From 
this follows a strategy of limiting the number of open heart surgeries, creating less 
inconvenience for patients. In Paper 3, a percutaneous approach was chosen for less 
than half of the patients. Conduit anatomy likely is the key to the feasibility of TPVR, 
and new and improved methods will have a considerable impact on the feasibility of 
TPVR in more patients. Given that long-term event-free survival after conduit reinter-
vention is shorter than after the fi rst conduit operation, it is reasonable to surmise that 
the need for reinterventions will be a major issue throughout the patient’s lifespan, 
with signifi cant impact on recurring symptoms and HRQoL (Paper 2). TPVR seems 
less inconvenient than surgery for the patient, and there is no indication in the litera-
ture that outcome after TPVR is worse in comparison with surgery. Thus I agree that 
“surgery when necessary, percutaneous when possible” is the best current approach. 
In practice, this should mean optimizing the fi rst conduit operation and then managing 
the patient with a percutaneous approach for as long as possible. Since the number of 
patients with a conduit is increasing (Paper 3), this will call for reallocation of health 
care resources to tertiary centers and expansive training of congenital heart interven-
tionists.
Decreasing event-free survival after the fi rst conduit reintervention is a concern. For 
patients undergoing repeated reinterventions with short event-free survival, this might 
call for an individualized approach. Possible approaches in such cases are optimizing 
anatomy if possible, changing conduit type, and in selected cases even treatment with 
ibuprofen.
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TPVR in nonconduit RVOTs should be considered in selected patients with suitable 
anatomy and increased surgical risk. This strategy can postpone the fi rst conduit op-
eration, which in some cases can be an advantage to the patient under lifetime man-
agement.
This study is not designed to compare different conduits. However, the vast majority 
of conduits in Sweden are homografts. Given the outcome data in this study in relation 
to others, I see no reason to question the use of homografts per se. Furthermore, there 
are no other studies in adults giving robust support to other conduits in preference 
to homografts. Recent data from other groups on the higher incidence of infectious 
endocarditis in xenografts and TPVRs in comparison with homografts lends yet more 
support to the use of homografts.
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CONCLUSIONS
Event-free survival after conduit surgery is close to 80% at 10 years, but the event-
free survival time signifi cantly shortens after conduit reinterventions. Long-term 
mortality after conduit surgery is low and dominated by cardiac-related death. The 
population of patients with a conduit is increasing, and conduit reinterventions are 
common. Since the introduction of TPVR, fewer than half of affected patients have 
received this treatment for conduit reintervention. Patients have declining perceived 
health over time after RVOT surgery, but such a decline was not observed in patients 
undergoing further reinterventions.
The data on outcome and QoL can be used in a structured multidisciplinary manage-
ment plan using complementary surgical and percutaneous methods to treat the pa-
tient during lifetime management.
46
FUTURE PERSPECTIVES
Mechanistic studies of failing conduits are needed for the further understanding of 
the pathophysiological process of conduit failure and the possibility of improving 
conduits. One way forward is to study the relationship between conduit hemodynamic 
defects, infl ammation, and subsequent degeneration.
Further studies on the decision for surgery versus TPVR can also be useful. There are 
other relevant factors (e.g., proximity to coronary arteries, conduit size) beyond the 
scope of this study. One possible study design would be assessment of the decisions 
taken during multidisciplinary conferences at tertiary sites.
It is essential that we have knowledge of the optimal timing for PVR. This is impor-
tant both at initial repair and in reoperations. The fact that timing of procedures in 
childhood is refl ected in outcome in adults indicates that there are very long cycles of 
follow up before the results of decisions taken in pediatric care can be transitioned to 
improved outcomes in adults. One example is the possible benefi ts of a very proactive 
surgical approach to PVR in children, aiming at a very limited gradient and no PR. 
This calls for increasing collaboration between adult and pediatric care. Furthermore, 
low mortality and a time interval of often a decade until reoperations make it chal-
lenging to study the effects of outcome changes in practice. Multicenter studies and 
international collaboration are needed in this area of research.
The SWEDCON registry offers a possibility to perform registry-based randomized 
controlled trials in this fi eld.
Patients with a conduit have a lifelong need for follow up. Recurring symptoms and 
the need for reintervention likely has an impact on HRQoL. Further research on lon-
gitudinal HRQoL and patient-reported outcomes and experience could help, also in 
relation to outcomes after various procedures such as surgical PVR or TPVR.
There is also a need for improved materials. Conduits with better durability are an 
obvious example, but new and improved TPVRs for various anatomical settings in-
cluding native RVOTs are also required. Since reintervention is common, there is also 
a need for surgical preparation of RVOT as a landing zone for TPVR.
Given the importance of anatomy for conduit durability, one option could be to modu-
late the preoperative setting to improve the eventual outcome. There are studies of 
resection of RVOT aneurysm with neutral results, perhaps opening avenues to other 
approaches.
Both the durability and longevity of conduits are of major importance. There is a 
difference between echocardiographic failure and dysfunction requiring reoperation. 
Many patients likely live with dysfunctional conduits for many years. Further study 
of differences in tolerability is warranted.
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Appendix Paper 3 and 4
SWEDCON/GUCH is supposed to cover all conduit procedures in Sweden. Patients 
with conduit were identifi ed using the group variable EPGID 1017 in SWED-
CON/GUCH. This variable is unique to patients with RV to PA conduits. 
Codes for classifying surgical procedures were used to identify relevant surgical pro-
cedures and TPVR (www.nordclass.se/NCSP_1_16.pdf).The procedures were 
defi ned as follows: 
Conduit surgery: FDC 00, FDC 10, FDC 20, FDC 96, FHE 40, FHF 10, FHF 30, FHG 
20, FJD 20, FJF 10, FJF 20, FMD 40, and FMW 96. 
Transcatheter pulmonary valve replacement (TPVR): FJF 12 or FJF 96.
